Format

Send to

Choose Destination
Dermatol Ther (Heidelb). 2019 Aug 2. doi: 10.1007/s13555-019-00316-3. [Epub ahead of print]

Dissolving Triamcinolone-Embedded Microneedles for the Treatment of Keloids: A Single-Blinded Intra-Individual Controlled Clinical Trial.

Author information

1
National Skin Centre, Singapore, Singapore.
2
Institute of Infocomm Research, Agency for Science, Technology and Research, Singapore, Singapore.
3
SERI-NTU Advanced Ocular Engineering (STANCE), Singapore, Singapore.
4
National Skin Centre, Singapore, Singapore. teyhongliang111@yahoo.com.
5
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. teyhongliang111@yahoo.com.
6
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. teyhongliang111@yahoo.com.

Abstract

INTRODUCTION:

Keloids are a prevalent chronic skin disorder with significant psychosocial morbidity. Intralesional corticosteroid injections are the first-line treatment but are painful and require repeated injections by medical professionals. Dissolving microneedles are a novel method of cutaneous drug delivery that induces minimal/no pain and can be self-administered. The objective of the study was to evaluate the efficacy and safety of triamcinolone-embedded dissolving microneedles in treatment of keloids.

METHODS:

This was a single-blind, intra-individual controlled two-phase clinical trial of 8-week duration each. Two keloids per subject were selected for (1) once-daily 2-min application with microneedles for 4 weeks, followed by no treatment for the next 4 weeks, or (2) non-intervention as control. Primary outcome was change in keloid volume as assessed by a high-resolution 3D scanner.

RESULTS:

There was significant reduction in keloid volume compared with controls after 4 weeks of treatment. This reduction was greater with a higher dosage of triamcinolone used.

CONCLUSIONS:

Once-daily application of dissolving triamcinolone-embedded microneedles significantly reduced the volume of keloids. The treatment was safe, can be self-administered and can serve as an alternative for patients unsuitable for conventional treatments.

TRIAL REGISTRATION:

Trial Registry: Health Science Authority (Singapore) Clinical Trials Register Registration number: 2015/00440.

KEYWORDS:

Keloids; Microneedles; Scars

PMID:
31376063
DOI:
10.1007/s13555-019-00316-3

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center